key: cord-0906904-k7x4xw1b
authors: Salaris, Claudio; Scarpa, Melania; Elli, Marina; Bertolini, Alice; Guglielmetti, Simone; Pregliasco, Fabrizio; Brun, Paola; Castagliuolo, Ignazio
title: Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells
date: 2021-08-07
journal: Gut microbes
DOI: 10.1080/19490976.2021.1961970
sha: f9b9246d25df2b319bcbd5bf1281e110517b25d5
doc_id: 906904
cord_uid: k7x4xw1b

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the ongoing global pandemic of coronavirus disease 2019 (COVID-19), which primarily manifests with respiratory distress and may also lead to symptoms associated with the gastrointestinal tract. Probiotics are living microorganisms that have been shown to confer immune benefits. In this study, we investigated the immunomodulatory effects and anti-SARS-CoV-2 activity of three different Lacticaseibacillus probiotic strains, either alone or in combination with lactoferrin, using the intestinal epithelial Caco-2 cell line. Our results revealed that the Lacticaseibacillus paracasei DG strain significantly induced the expression of genes involved in protective antiviral immunity and prevented the expression of proinflammatory genes triggered by SARS-CoV-2 infection. Moreover, L. paracasei DG significantly inhibited SARS-CoV-2 infection in vitro. L. paracasei DG also positively affected the antiviral immune activity of lactoferrin and significantly augmented its anti-SARS-CoV-2 activity in Caco-2 intestinal epithelial cells. Overall, our work shows that the probiotic strain L. paracasei DG is a promising candidate that exhibits prophylactic potential against SARS-CoV-2 infection.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped virus with a singlestranded positive-sense RNA genome, 1 is a novel coronavirus that generated a pandemic outbreak, designated coronavirus disease 2019 (COVID- 19) , which was initially identified in Wuhan, China, in December 2019 and spread rapidly worldwide. 2 COVID-19 has emerged as a multifaceted, multisystem and multiorgan disorder ranging from nonspecific flu-like symptoms to pneumonia, acute respiratory distress syndrome (ARDS), multiple organ failure and death. 2,3 SARS-CoV-2 infection starts by the binding of the virus spike surface glycoprotein (SgP) to host cell surface heparan sulfate proteoglycans (HSPGs) and angiotensinconverting enzyme 2 (ACE2) receptors present on many human cells, which are then cleaved by host proteases, thus allowing virus internalization into host cells. 4 SARS-CoV-2 appears to primarily spread through respiratory droplets and secretions, but the gastrointestinal tract could be another potential route of infection, since in approximately 17% of cases, gastrointestinal disorders are associated with respiratory symptoms. 5 These data suggest that the gastrointestinal tract might be a location of viral activity and replication, in line with the high expression of ACE2 in the intestinal epithelium. 6 Currently, therapeutic interventions against SARS-CoV-2 infection rely on supportive care and symptom alleviation, with just one conditionally authorized antiviral treatment regimen for COVID-19 7 and several effective specific treatments still under investigation. [8] [9] [10] Emergency use of four vaccines has been recently authorized 7, while several other vaccine candidates are still being evaluated in phase III trials. 11 Thus, novel preventative and treatment strategies for SARS-CoV-2 infection are crucial to relieve the public health, economic and societal impacts of the virus.

Probiotics, defined as live microorganisms that when administered in adequate amounts, confer a health benefit on the host, 12 act on both the innate and acquired immune systems and have the potential to decrease the severity of infections in the gastrointestinal 13 and upper respiratory tracts. 14 They exert antiviral activity by direct probioticvirus interactions, production of antiviral inhibitory metabolites, and stimulation of the type I interferon response and antibody production against viruses. [15] [16] [17] The potential for probiotics to reduce the risk and severity of viral respiratory tract infections is also supported by clinical and experimental studies on influenza, rhinovirus, and respiratory syncytial virus. 18, 19 Although none of these effects have been tested with SARS-CoV-2, some probiotic strains do have antiviral activity against other coronaviruses. [20] [21] [22] The Lactobacillaceae family includes most of the microbial strains used in probiotic food and supplements. 23 It consists of gram-positive fermentative bacteria, including species that are important members of the microbial ecosystems of human mucosae, such as those of the intestinal tract and vagina. 24 Considering the important contribution that these microorganisms may exert for host immunity, it has been suggested to provide COVID-19 patients with nutritional support and prebiotic or probiotic supplementation to renormalize the intestinal microbiota community structure and decrease the risk of infection. 25 However, no study has addressed whether Lactobacillus spp. can affect intestinal antiviral immunity and SARS-CoV-2 infection.

Lactoferrin (LF) is a naturally occurring multifunctional glycoprotein with broad-spectrum antiviral, immunomodulatory and anti-inflammatory effects. 26, 27 LF was shown to block multiple common human coronaviruses and SARS-CoV-2 invitro 28, 29 by preventing the interaction between the viral particle and its cell receptors, represented by HSPGs, 30 which act as necessary cofactors for SARS-CoV-2 infection. 31 The studies supporting the immune benefits and antiviral activity of probiotics prompted us to hypothesize that Lacticaseibacillus strains could affect the antiviral immune response and SARS-CoV-2 infection of intestinal cells. Therefore, the present work aimed to investigate the in vitro antiviral immunomodulatory effects of three different Lacticaseibacillus strains, either alone or in combination with LF. Furthermore, their antiviral activity was evaluated in an in vitro model of SARS-CoV-2 infection. Based on our findings, we propose that the Lacticaseibacillus paracasei DG strain is a promising probiotic useful for the prevention of SARS-CoV-2 infection and alleviation of associated symptoms.

The human colon adenocarcinoma cell line Caco-2 (ATCC®HTB-37™) and monkey kidney epithelial cell line Vero E6 (ATCC®CRL-1586™) were grown in DMEM (Gibco-Thermo Fisher Scientific, Waltham, USA) supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) sodium pyruvate and 1% (v/v) penicillin/streptomycin (all from Gibco-Thermo Fisher Scientific, Waltham, USA) at 37°C in a humidified incubator containing 5% CO 2 .

Lactobacillus strains, namely, Lacticaseibacillus rhamnosus (formerly Lactobacillus rhamnosus) GG (ATCC 53103), L. paracasei (formerly Lactobacillus paracasei) DG (CNCM I-1572; L. paracasei DG®; Enterolactis®, SOFAR S.p.A.) and L. paracasei LPC-S01 (DSM 26760) were cultured on De Man Rogosa Sharpe (MRS) plates (Difco, BD). The strains were incubated for 72 h at 37°C under anaerobic conditions. Strain ATCC 53103 was purchased from the American Type Culture Collection (ATCC), while strains DG and LPC-S01 were provided by Sofar S.p.A. (Milan, Italy). LF was acquired as Globoferrina® (Sofar, Italy). LF was used alone and/or in combination with the probiotics at a final concentration of 100 µg/ml. Sterile DMEM (Gibco-Thermo Fisher Scientific, Waltham, USA) supplemented with 20% glycerol was added as a control test. Remdesivir (Apollo Scientific, Bredbury, UK) was used as an antiviral control for our assays. Remdesivir was used alone for 3 h at a final concentration of 10 μM.

SARS-CoV-2 was isolated from a patient at the Microbiology Unit, University Hospital Padua. The viral strain was propagated and titrated as previously described. 28 See Supplementary Methods for details. All the infection experiments were performed in a biosafety level 3 (BSL-3) laboratory at the Department of Molecular Medicine, University of Padova, Padova, Italy.

Broth cultures were prepared in MRS broth with incubation for 18 h at 37°C under anaerobic conditions. Following incubation, the strains were centrifuged for 10 min at 3000 rpm, and the cell pellets were washed twice with sterile distilled water. The optical density at 600 nm (OD 600 ) of washed cultures was adjusted to 0.3 to reach 2.5 × 10 6 colonyforming units (CFU) in a 20 µl volume. Standardized washed cultures were serially diluted for viable counts and centrifuged for ten minutes at 3000 rpm. The pellets were resuspended in sterile DMEM (Gibco-Thermo Fisher Scientific, Waltham, USA) supplemented with 20% glycerol (Merck).

Caco-2 cells were seeded in 12-well plates (2 × 10 5 cells/mL). After reaching confluence, the cells were washed in phosphate-buffered saline (PBS; Gibco-Thermo Fisher Scientific, Waltham, USA) and incubated in antibiotic-free medium (AFM) or subjected to one of the following treatments described below, according to the experimental design displayed in Supplementary Figure S1 . In all treatment protocols, confluent Caco-2 cells were supplemented with the bacterial strain (multiplicity of infection (MOI) of 10:1 bacteria: cells). LF was added at a concentration of 100 μg/ml with or without the bacterial strain. After 3 h, in the probiotic treatment experiments, cells were washed in PBS (Gibco-Thermo Fisher Scientific, Waltham, MA, USA) and incubated with fresh medium supplemented with antibiotics (penicillin/streptomycin). The cells were harvested 24 h later for RNA extraction. In the probiotic pre-infection treatment protocol, cells were washed in PBS (Gibco-Thermo Fisher Scientific, Waltham, MA, USA), supplemented with fresh medium with antibiotics (penicillin/ streptomycin) and infected with SARS-CoV-2 (MOI 2:1) for 1 h. Twenty-four hours post infection, the cells were harvested for RNA extraction, and the supernatants were harvested for viral titration.

Total RNA was isolated, and gene expression analysis was performed as previously reported. 28 The specific forward and reverse primers used are summarized in Supplementary Table S1 . Data are presented as the mean fold change over the control.

Caco-2 cells were seeded in sterile coverslips inside 6-well plates. After reaching confluence, the cells were subjected to one of the previously described treatments and infected with SARS-CoV-2 at an MOI of 2:1. Staining was performed as previously described. 28 See Supplementary Methods for details.

All experiments were performed in duplicate wells for each condition and repeated at least three times. Data are shown as the mean +/− SD. Statistical analysis was performed using GraphPad Prism Software 6.0 (GraphPad Software Inc., La Jolla, USA). Comparisons were performed using oneway ANOVA for multiple comparisons as indicated in each figure legend. Differences among and between individual groups were compared as indicated in each figure legend, with P ≤ 0.05 considered significant.

The antiviral immunomodulatory effects of probiotic Lacticaseibacillus strains were evaluated in vitro using the human intestinal epithelial cell line Caco-2. LF, a common nutritional supplement known for its immunomodulatory properties, was also tested for reference. As shown in Figure 1 , probiotic treatment induced significant changes in the expression profile of several genes involved in the antiviral immune response. The levels of the antiviral cytokines interferon alpha (IFNA1) and beta (IFNB1) were significantly enhanced by L. paracasei DG (Figure 1a) . Moreover, L. paracasei DG significantly augmented the expression of TLR7, a pattern recognition receptor involved in RNA virus sensing; IFIH1, the gene encoding MDA5, which is a molecular sensor of viral RNA; and IRF7 and MAVS, which participate in antiviral response signaling pathways (Figure 1b and 1c) . Notably, L. paracasei DG significantly triggered the upregulation of IFNA1, IFNB1, TLR7, IFIH1, IRF7 and MAVS transcript levels compared to those with the other probiotic strains, which showed a trend toward the upregulation of the aforementioned genes. These results reveal that all three probiotic strains can stimulate different levels of antiviral immunity activity, with L. paracasei DG being the most promising in terms of significant upregulation of the expression of all the genes tested.

Considering the ability of LF to stimulate the antiviral immune response, 28 its effectiveness when used in combination with probiotic Lacticaseibacillus strains was evaluated. When Caco-2 cells were treated with LF and L. paracasei LPC S01 in combination or with LF and L. rhamnosus ATCC 53103 in combination, no significant improvement was observed in the expression of genes involved in the antiviral immune response compared to that with L. paracasei LPC S01, L. rhamnosus ATCC 53103 or LF treatments alone ( Figure 2) . Notably, treatment of Caco-2 cells with L. paracasei DG together with LF significantly improved the activity of the antiviral immune response by increasing the expression of the IFNA1, TLR3 and IRF7 genes compared to that with L. paracasei DG treatment . Data are shown as the relative fold change compared to the untreated control (arbitrarily set as 1) and presented as the mean ± SD. *P < .05 ****P < .0001 vs untreated; # P < .05, ## P < .01, ### P < .001, #### P < .0001 vs L. paracasei DG; and § § § § P < .0001 vs LF based on one-way ANOVA (followed by Bonferroni's multiple comparison test). alone ( Figure 2 ). The effectiveness of this combination was also significantly higher than that of LF alone in terms of upregulation of IFNA1, IFNB1, TLR7, IFIH1, IRF7 and MAVS gene expression. These results suggest that L. paracasei DG ameliorates the in vitro immunostimulation activity of LF.

To evaluate the antiviral activity of the different probiotic strains against SARS-CoV-2, an infection assay for SARS-CoV-2 was performed in Caco-2 cells. Prior to virus infection, cells were pre-treated with probiotic strains for 3 h and then infected with SARS-CoV-2 for 1 h (Supplementary Figure S1) . Remdesivir treatment was used as a positive control. The expression level of the virus-specific genes encoding RNA-dependent RNA polymerase (RdRp) and the E gene (CoVE), critical for SARS-CoV-2 replication and assembly, was analyzed from total RNA obtained from harvested cells. As shown in Figure 3a , the expression of both genes was significantly reduced in L. paracasei DG-treated Caco-2 cells, indicating that pretreatment with the probiotic strain could inhibit SARS-CoV-2 replication in vitro. Furthermore, when Caco-2 cells were pre-treated with LF and the three probiotic strains in combination, no significant improvement was observed in the inhibition of the expression of SARS-CoV-2 genes compared to that with LF pre-treatment alone (Figure 3b ). Only pre-treatment of Caco-2 cells with L. paracasei DG together with LF tended to improve the antiviral activity of L. paracasei by further reducing the expression of the RdRp gene in comparison to that with LF alone pre-treatment. Thus, we next evaluated the SARS-CoV-2 titer in the harvested supernatants: pre-treatment with all tested conditions significantly diminished viral titers compared to that of the infection control, with L. paracasei DG alone or in combination with LF resulting in 41.5 ± 4.8% and 49.7 ± 4.4% inhibition of SARS-CoV-2 infection, respectively (Figure 3c ).

Lacticaseibacillus probiotic strains (n = 5). Data are shown as the relative fold change compared to the untreated control (arbitrarily set as 1) and presented as the mean ± SD. *P < .05, **P < .01, ****P < .0001 vs L. paracasei DG without LF; # P < .05, ## P < .01, ### P < .001, #### P < .0001 vs L. paracasei DG with LF; and § P < .05, § § § P < .001, § § § § P < .0001 vs LF based on one-way ANOVA (followed by Bonferroni's multiple comparison test).

Moreover, immunofluorescence staining of Caco-2-infected cells for the viral spike glycoprotein confirmed that L. paracasei DG both alone and in combination with LF decreased SARS-CoV-2 infection and replication in Caco-2 cells (Figure 3d) . . Data are shown as the relative fold change compared to the untreated (infected) control (arbitrarily set as 1) and presented as the mean + SD. *P < .05, **P < .01 vs untreated infected based on one-way ANOVA (followed by Dunnett's multiple comparison test). (c) The SARS-CoV-2 titer was determined by plaque assay performed on harvested supernatants; the titer (plaque-forming units (PFU)/ml) in the supernatants as well as the percentage of inhibition of infection are represented. **P < .01, ****P < .0001 vs untreated infected; and § § § P < .001, § § § § P < .0001 vs LF based on one-way ANOVA (followed by Dunnett's multiple comparison test). (d) Representative staining for SARS-CoV-2 spike in infected Caco-2 cells pre-treated or not with lactoferrin or L. paracasei DG alone or together with lactoferrin.

Proinflammatory cytokine levels are known to be elevated by SARS-CoV-2 infection, and in the most severe cases, patient prognosis can be markedly worsened along with the hyperproduction of proinflammatory cytokines. To determine whether pretreatment with probiotic strains could be protective against the inflammatory response triggered by SARS-CoV-2 infection in vitro, the expression profile of inflammatory and anti-inflammatory cytokines in SARS-CoV-2-infected Caco2 cells pre-treated or not with Lacticaseibacillus cells was tested (Figure 4) . The transcript levels of all the measured cytokines tended to be upregulated following infection with SARS-CoV -2 (data not shown). Notably, pre-treatment of infected Caco-2 cells with the L. paracasei DG strain significantly reduced the mRNA expression levels of the IL6, CXCL8, TSLP and TGFB1 genes and augmented the transcript levels of IL10 compared to those in the control (Figure 4a and 4b) . This effect might be explained by the reduced viral load present following the antiviral activity of the L. paracasei DG strain; however, it could also be partially detected in infected Caco-2 cells pre-treated with the other probiotic strains, which showed minor antiviral activity. Overall, L. paracasei DG protective activity against the inflammatory response induced by SARS-CoV-2 was still effective but not improved when in combination with LF supplementation (Supplementary Figure S2) .

Recently, a sizable number of reviews and opinion articles summarizing the antiviral effects of . Data are shown as the relative fold change compared to the untreated (infected) control (arbitrarily set as 1) and presented as the mean + SD. **P < .01, ***P < .001, ****P < .0001 vs untreated infected based on one-way ANOVA (followed by Dunnett's multiple comparison test).

probiotics and their potential contribution in preventing and fighting virus infections with special focus on COVID-19 have been published. These publications support the administration of probiotics to patients with COVID-19 despite the absence of solid evidence supporting whether these treatments can prevent or treat this infectious disease. However, boosting the natural immunity of the population using probiotics before, during, or after COVID-19 infection is rational. In the present study, we report for the first time experimental evidence supporting the use of the L. paracasei DG strain for the prevention of SARS-CoV-2 infection.

Among the probiotic strains tested, L. paracasei DG was the most promising in terms of antiviral immunomodulatory activity and was able to induce the expression of IFN genes and genes involved in antiviral response signaling pathways, such as TLR7, IFIH, IRF7 and MAVS. This finding is of special interest in the context of SARS-CoV-2 infection. Coronaviruses have various mechanisms to evade the innate immune response, especially by modifying the type I IFN response. 32 In comparison with other respiratory viruses, SARS-CoV -2 induces a lower antiviral transcriptional response marked by low type I IFN levels and elevated chemokine expression. 33 Furthermore, patients with severe COVID-19 exhibit an impaired type I IFN response and reduced viral clearance. 34 In addition, whole-genome sequencing of SARS-CoV, MERS-CoV, and SARS-CoV -2 has shown that the SARS-CoV-2 genome contains more single-stranded RNA motifs that could interact with TLR7 than the SARS-CoV genome, indicating that TLR7 signaling might be even more relevant in the pathogenesis of COVID-19. 35 In a case series of 4 young male patients with severe COVID-19, rare putative loss-offunction variants of X-chromosomal TLR7 were identified that were associated with impaired type I and II IFN responses. 36 Our results showed not only the antiviral immune boosting activity of L. paracasei DG but also its ability to suppress SARS-CoV-2 replication in vitro by approximately 50%. Indeed, lactic acid bacteria (LAB) probiotics, such as L. paracasei DG, produce a wide variety of antimicrobial compounds, such as hydrogen peroxide, lactic acid and bacteriocin-like inhibitory substances, which have shown the ability to decrease viral loads. 37 Proposed modes of antiviral action include direct interaction between the LAB and viruses, production of antiviral substances and stimulation of the host's immune system. 17 In the context of SARS-CoV-2 infection, lactobacilli may act as a barrier to viral penetration through several mechanisms. 38 Lactobacillus gasseri Kx110A1 was reported to attenuate SARS-CoV-2 infection by inhibiting the expression of a disintegrin and metalloprotease 17 (ADAM 17), 39 an enzyme that participates in ACE2 ectodomain shedding and that has been shown to play a role in the entry of SARS-CoV, since ADAM17 silencing was found to reduce SARS-CoV infection. 40 Moreover, a computational study found that plantaricin, a bacteriocin secreted by Lactiplantibacillus plantarum, may possess SARS-CoV-2 antiviral activity by interacting with the receptor-binding domain (RBD) of the viral spike glycoprotein and thus blocking SARS-CoV-2 cellular entry. 41 Some lactobacilli have been reported to release peptides with high affinity for ACE during milk fermentation. 42 Although the mechanism supporting the antiviral activity of L. paracasei DG observed in this study is not known, we can speculate that the unique rhamnose-rich heteroexopolysaccharide molecule that covers the cells of this bacterium may contribute to the peculiar cross-talk of DG with host cells. 43 Indeed, a limitation of our study was the inability to determine the essential molecules produced by L. paracasei DG required to inhibit SARS-CoV-2 replication. Additionally, the detailed molecular mechanisms by which L. paracasei DG and LF inhibit viral replication need to be elucidated. The LF antiviral mechanisms vary among viruses, where it may bind either directly to the virus particle or to the host cell receptor or coreceptor. 44 Based on our results, it seems that the L. paracasei DG and LF combination has additive antiviral and immunomodulatory effects, thus implying that they function independently without interfering with each other's mechanism of action.

An unbalanced immune response, characterized by a weak production of type I interferons and an exacerbated release of proinflammatory cytokines, contributes to the severe forms of COVID-19. 45 Moreover, low-grade chronic systemic e1961970-8 C. SALARIS ET AL.

inflammation accompanies several comorbidities that adversely affect the outcomes of patients with COVID-19. 46 Our results show that prophylactic treatment with L. paracasei DG in vitro suppressed the inflammatory response triggered by SARS-CoV-2 infection in Caco-2 cells, as the transcript levels of the proinflammatory cytokines IL-6, CXCL8 and TSLP were reduced compared to those in the control. The anti-inflammatory potential of strain DG was also evidenced in previous in vitro experiments since it was demonstrated to significantly reduce the activation of NF-κB in Caco-2 cells, 47 and its administration in vivo significantly diminished inflammatory cytokine levels and increased mucosal IL-10 levels in ulcerative colitis patients upon rectal administration. 48 Thus, L. paracasei DG preventive use may contribute to the alleviation of the excessive inflammatory response induced by SARS-CoV-2 infection.

Previous studies using several probiotic species and strains showed that their immunomodulatory effects were strain specific. 49 Our results revealed different antiviral immunity activities as well as distinct levels of inhibition of SARS-CoV-2 among the three tested probiotic strains. In particular, we found that the antiviral properties of L. paracasei DG were better than those of LPC-S01, a probiotic strain belonging to the same species as strain DG, confirming that the immunological effects of probiotics are strain-specific features. 12 In addition, L. paracasei DG displayed enhanced activities compared to those of L. rhamnosus GG, the most extensively studied and one of the most widely used probiotics worldwide, which has been documented to exert immunomodulatory properties. 50 Since the ability to affect host immune responses is primarily strain specific, the choice of effective strains of probiotics is fundamental for the development of novel and targeted approaches for gut microbiota modulation as a preventive strategy against COVID-19. Here, we propose L. paracasei strain DG as a promising candidate for this purpose.

The efficacy of probiotics in COVID-19 patients remains to be proven, and the issue is under debate. 51, 52 Several clinical studies of probiotic intervention in COVID-19 are underway. 53 In conclusion, our work showed that the probiotic strain L. paracasei DG is a promising candidate that exhibits prophylactic potential against SARS-CoV-2 infection. The characterization of L. paracasei DG mechanisms that enable inhibition of SARS-CoV-2 replication, as well as of its effect in vivo, represent an important future research direction.

No potential conflict of interest was reported by the author(s).

This work was fifinancially supported by Sofar S.p.A.

http://orcid.org/0000-0002-7055-635X Paola Brun http://orcid.org/0000-0002-3279-9000 Ignazio Castagliuolo http://orcid.org/0000-0001-9888-7030

The data presented in this study are available on request from the corresponding author.

A novel coronavirus from patients with pneumonia in China

Clinical features of deaths in the novel coronavirus epidemic in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a hong kong cohort: systematic review and meta-analysis

Multiomics evaluation of gastrointestinal and other clinical characteristics of COVID-19

European medicines agency 2021

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients

Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrobial agents and chemotherapy

Potential therapeutic options for COVID-19: current status, challenges, and future perspectives

SARS-CoV-2 vaccines in development

Expert consensus document. the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic

Probiotics for prevention and treatment of diarrhea

Probiotics in respiratory virus infections

Probiotics in viral infections, with a focus on COVID-19: a systematic review

Role of probiotics to combat viral infections with emphasis on COVID-19

Probiotics at war against viruses: what is missing from the picture? Front Microbiol Internet

Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis

Probiotics for preventing acute upper respiratory tract infections. The cochrane database of systematic reviews

Putative probiotic Lactobacillus spp. from porcine gastrointestinal tract inhibit transmissible gastroenteritis coronavirus and enteric bacterial pathogens. Tropical Animal Health and Production

Antiviral effects of a probiotic enterococcus faecium strain against transmissible gastroenteritis coronavirus

Surface-displayed porcine IFN-λ3 in lactobacillus plantarum inhibits porcine enteric coronavirus infection of porcine intestinal epithelial cells

Microorganisms with claimed probiotic properties: an overview of recent literature

Lactobacillaceae in the

Encyclopedia of metagenomics

The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19

Lactoferrin as protective natural barrier of respiratory and intestinal mucosa against coronavirus infection and inflammation

Immune-Boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19

Protective effects of lactoferrin against SARS-CoV-2 infection in vitro

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans

Infection depends on cellular heparan sulfate and ACE2. Cell

Available from

SARS and MERS: recent insights into emerging coronaviruses

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes

Presence of genetic variants among young men with severe COVID-19

Antiviral potential of lactic acid bacteria and their bacteriocins

Respiratory syndrome coronavirus-2 response: microbiota as lactobacilli could make the difference

Lactobacillus gasseri suppresses the production of proinflammatory cytokines in helicobacter pylori-infected macrophages by inhibiting the expression of ADAM17

Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry

Antiviral effects of probiotic metabolites on COVID-19

Novel angiotensin-converting enzyme-inhibitory peptides from fermented bovine milk started by lactobacillus helveticus KLDS.31 and lactobacillus casei KLDS.105: purification, identification, and interaction mechanisms

Heteroexopolysaccharide isolated from lactobacillus paracasei DG activates THP-1 human monocytic cells

The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19

Interplay between SARS-CoV-2 and the type I interferon response

The clinical characteristics and risk factors of severe COVID-19

The vaginal isolate Lactobacillus paracasei LPC-S01 (DSM 26760) is suitable for oral administration

Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis

Nutritional modulation of immune function: analysis of evidence, mechanisms, and clinical relevance

Probiotics and COVID-19

Probiotics and COVID-19: one size does not fit all

Review article: probiotics, prebiotics and dietary approaches during COVID-19 pandemic

Conceptualization, C.S., P.B. and I.C.; investigation, C.S., M. E. and A.B.; data curation, M.S. and P.B.; writing-original draft preparation, M.S.; writing-review and editing, S.G., F. P. and I.C. All authors have read and agreed to the published version of the manuscript.